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The aim of the study was to analyse the relationship
between the serum level of vascular endothelial growth
factor (VEGF) and the incidence of hypertension (HT) in
children and adolescents with type I diabetes mellitus
(T1DM). One hundred and five patients with T1DM were
enrolled in the study. The control group consisted of 30
healthy controls. All the T1DM patients were subjected to
biochemical analyses, ophthalmologic examination and
24-h blood pressure monitoring. Besides, all the patients
and healthy controls had serum VEGF levels measured
with the use of the ELISA methodology. The essence of
our research is that patients with T1DM and HT and with
microalbuminuria (MA) and diabetic retinopathy (DR) (MA/
DR) are characterized by a significantly higher level of
VEGF (340.23±93.22pgml
–1) in blood serum in compar-
ison with the group of T1DM patients without HT and
MA/DR (183.6±96.6pgml
–1) and with healthy controls
(145.32±75.58pgml
–1). In addition, the VEGF level was
significantly higher in T1DM patients, who presented all
three complications, that is HT, retinopathy and MA
in comparison with T1DM patients without HT, but with
MA/DR (P¼0.036). On the other hand, no statistically
significant differences (P¼0.19) were noted in the level of
VEGF in serum between T1DM patients without HT and
MA/DR and the healthy control group. At a further stage of
analysis, using the method of multiple regression, it was
shown that systolic pressure, HbA1c and duration of
disease are independent factors influencing the concen-
tration of VEGF. Summarizing, the measurement of VEGF
serum levels allows for the identification of groups of
patients who have the highest risk of HT and, subse-
quently, progression of vascular complications.
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Introduction
In recent years, a dramatic increase in the incidence
of diabetes in developed countries has been ob-
served.
1–3 Accordingly, also in Poland in the last
decade, a significant increase in type I diabetes
mellitus (T1DM) incidence has been reported for the
paediatric population.
4–6 Along with increased in-
cidence of diabetes, the risk of development of
diabetic microvascular complications, as well as the
percentage of patients with arterial hypertension
(HT), has also increased.
7–9 According to various
estimations, 1–5% of children have HT.
10,11 It has
also been shown that elevated blood pressure is 2–3
times more frequent in diabetic patients as com-
pared with the general population.
12 It is suggested
that, in the course of T1DM, the presence of elevated
values of arterial blood pressure is associated with
the development of diabetic nephropathy and
retinopathy.
13–15 Apart from HbA1c, which is a
well-known risk factor for micro- and macrovascular
complications, recent data suggest that growth
factors, including vascular endothelial growth factor
(VEGF), may have an important function in the
modification of tissue damage and its accelera-
tion.
16–19 It was shown that VEGF induces vascular
endothelial cell proliferation and migration and
increases the permeability of renal glomerular and
retinal capillaries.
18–20
There is solid experimental and clinical evidence
of the function of VEGF in retinal angiogenesis.
Retinal hypoxia leads to a pronounced increase in
VEGF levels in several cell types, including peri-
cytes, Muller cells, astrocytes, retinal endothelial
cells and retinal pigment epithelial cells.
13,21–25
From literature, it is known that the serum VEGF
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Hermandez et al.
21 have shown that elevated VEGF
level in the aqueous humour correlated with
increased serum VEGF and was statistically signifi-
cantly higher in relation to the healthy control
group. A pilot study performed by Lip et al.
22
showed that patients with hypertensive retinopathy
had increased serum levels of VEGF and its soluble
receptor Flt-1. In our earlier studies, we have
documented the significance of VEGF in non-
proliferative retinopathy development in children
and adolescents with T1DM.
23–24 Others have also
shown the upregulation of VEGF mRNA expression
in pericytes as well as podocytes and mezangial
cells in the early stages of disease, indicating its
function in diabetic angiopathy.
20,25 The VEGF is the
strongest inducer of both physiological and patho-
logical angiogenesis.
17,26 Five different types, such
as VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and
eight isoforms of this cytokine are known (VEGF121,
VEGF145, VEGF148, VEGF162, VEGF165, VEGF183,
VEGF189, VEGF206). The VEGF isoforms differ in
the length of the amino-acid chain, mitogenic
activity and the VEGF receptors and heparin-bind-
ing affinities.
19,26,27 The VEGF exerts its biological
effects by binding to two surface tyrosine kinase
receptors. The VEGF receptor-1 (VEGFR-1) and
VEGF receptor-2 (VEGFR-2) are predominantly ex-
pressed on vascular endothelial cells. The VEGF
receptor-2 seems to be the main mediator of
angiogenesis and vasopermeability.
27
Adult HT is easily defined by sustained blood
pressure 4140/90mmHg, whereas no single cutoff
point defines HT in a paediatric patient, making
identification of childhood HT more difficult.
28,29
According to the Second National Heart, Lung and
Blood Institute Task Force, HT is defined as an
average systolic and/or average diastolic blood
pressure X95th percentile for age, sex and height
measured on at least three separate occasions.
30,31
Till now, the only available tool for predicting HT
was 24-h ambulatory blood pressure monitoring.
Hence, our study is aimed to search for early risk
factors of microangiopathy with HT, which would
become useful for the diagnosis of complication in
young patients with diabetes type I. Given that HTis
one of the most important factors influencing the
development of late vascular complications, we
have decided to analyse the levels of VEGF in
children and adolescents diagnosed with T1DM and
HT in relation to diabetes control and other clinical
parameters of the disease.
Material and methods
The study was carried out on 105 children and
adolescents with T1DM from the Department of
Paediatrics, Haematology, Oncology and Endocri-
nology of the Medical University of Gdan ´sk and on
30 healthy children and adolescents as a control
group. T1DM was defined in accordance with the
criteria of the American Diabetes Association.
32
Laboratory examinations
HbA1c was measured with an immunoturbidometric
method using Unimate 3 set (Hoffmann-La Roche AG,
Basel, Switzerland) with a normal range of values
3.0–6.0%. Fasting glucose was measured by enzymatic
test (Roche Diagnostics GmbH, Mannheim, Germany).
The level of CRP was measured with immunochem-
ical system (Beckman Instr. Inc., Galway, Ireland).
The level of C-peptide was below 0.5ngml
–1 in all
c h i l d r e nw i t hT 1 D M .T h eu r i n a r ya l b u m i ne x c r e t i o n
was expressed as the average of the three 24-h
collections obtained during 6 months before enrol-
ment into the study. Cases were classified as micro-
albuminuria (MA) when in at least two out of three
urine samples albumin excretion was between 30–
299mg per 24h. The urinary albumin excretion is
measured by immunoturbidometric assay using Tina-
quant (Boehringer Mannheim GmbH, Mannheim,
Germany). The serum level of creatinine was mea-
sured with the use of CREA assay system (Boehringer
Mannheim GmbH). Ophthalmologic investigation was
performed in all children with T1DM. This included
visual acuity tests, intraocular pressure and anterior
segment estimation by slit lamp (Topcon SL-82,
Tokyo, Japan). The fundus examination was per-
formed after the installation of 1% Tropicamid to
obtain sufficient mydriasis. The examination was
performed using the þ90D lens (Ocular Instruments,
Inc, Bellevue, WA, USA). A digital camera (Topcon
Imaginet 2000, Tokyo, Japan) was used to perform the
fluorescein angiography. Analysis of the eye fundus
pictures was based on The International Diabetic
Retinopathy Division.
33
Each patient was subjected to threefold 24-h
ambulatory blood pressure monitoring by the Holter
method. Various sizes of the cuff were used accord-
ing to the age and weight of the patient. The
apparatus was programmed to measure two time
spans: daily (600–2200 hours) and nocturnal (2200–
600 hours). All the ambulatory blood pressure
monitoring results, which had o80% of technically
correct measurements were excluded from the
study. In accordance with the report, The fourth
report on the diagnosis, evaluation and treatment of
high blood pressure in children and adolescents,
arterial HT was diagnosed when the blood pressure
value reached at least 95th percentile for the
corresponding age, gender and height on at least
three separate occasions.
31
The study was conducted on four groups: patients
with long-standing T1DM and diagnosed to have HT
and MA/diabetic retinopathy (DR) (n¼16); diabetic
patients without signs of HT and MA/DR (n¼74);
diabetic patients without HT, but with MA/DR
(n¼15) and a healthy control group (n¼30). The
clinical and biochemical parameters of the analysed
groups are summarized in Table 1.
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Journal of Human HypertensionAll patients with T1DM required insulin treat-
ment (0.87±0.24 Ukg
–1 of the body weight). Thirty
healthy children and adolescents volunteered as the
control group, after medical examination. Written
informed consent was obtained from all children
and adolescents participating in the study, or from a
parent or guardian.
This study was approved by The Ethics Commit-
tee of The Medical University of Gdan ´sk (NKEBN/
204/2009) and the investigation was carried out in
accordance with the principles of the Declaration of
Helsinki as revised in 1996.
Sample collection
Plasma samples were collected from 135 children and
adolescents. Blood samples were immediately placed
on ice, clarified by centrifugation at 3.000g for 5min
at 41C, and kept frozen at  801C until assayed.
Serum level of VEGF
Serum level of VEGF165 was measured by the ELISA
method (Quantikine High Sensitivity Human by
R&D System, Minneapolis, Minn., USA) in accor-
dance with the manufacturer’s protocol. Minimum
detectable concentrations were determined by the
manufacturer as 5.0pgml
–1. Intra-assay precision
was 53.7 and inter-assay 91% were determined on
20 replicates from the quality control data of the
laboratory.
Statistical analysis
All statistical analysis was undertaken with
the Statistica 8.0 software (StatSoft, Inc., Cracow,
Poland). The Shapiro–Wilk test was used to evaluate
normality of variables. Non-normal variables were
compared with non-parametric methods, that is the
Mann–Whitney U or the Kruskal–Wallis ANOVA.
Table 1 Clinical characteristics of T1DM patients and healthy subjects
T1DM patients with
HT with MA/DR
T1DM patients without HT Healthy
subjects
P
Without
MA/DR
With
MA/DR
n 16 74 15 30
Age (years) 17±4 15.8±2.9 16.6±3.6 16±4.0 P¼0.034*
P¼NS**
P¼0.36***
Diabetes onset (years) 7.3±3.3 7.6±3.6 7.2±3.9 — P¼NS*
P¼NS**
Duration of DM (years) 9.3±3.9 7.3±2.2 9.4±3.2 — P¼0.0001*
P¼NS**
HbA1C (%) 9.5±2.3 7.7±1.0 8.7±1.4 4.2±0.3 P¼0.0001*
P¼0.02**
P¼0.00001***
CRP (mgl
–1) 1.6±1.0 0.9±0.7 1.5±1.0 0.7±0.5 P¼0.0001*
P¼NS**
P¼0.16***
Albumin excretion rate (mg per 24h) 20.6 (3.1–115.2) 9.0 (0.9–28.8) 31.5(7.5–141.2) 2.8±1.2 P¼0.0001*
P¼NS**
P¼0.000001***
Creatinine in serum (mmoll
–1) 0.8±0.2 0.78±0.1 0.77±0.1 0.5±0.1 P¼NS*
P¼NS**
P¼0.0001***
SBP (mmHg) 129.0±7.0 108.0±8.0 110.0±9.0 110.0±8.0 P¼0.0001*
P¼0.008**
P¼0.001***
DBP(mmHg) 83.0±9.0 68.0±6.0 70.0±8.0 65.0±7.0 P¼0.0006*
P¼0.0003**
P¼0.0001***
VEGF (pgml
–1) 340.23±93.22 183.6±96.6 247.3±138.6 145.3±75.6 P¼0.035*
P¼0.036**
P¼0.00000***
Complications (n) 16 — 15 — 0.05*
Hypertension 16 — — — —
Microalbuminuria 15 — 10 — 0.03*
Non-proliferative retinopathy
and microalbuminuria
16 — 5 — 0.00001*
Abbreviations: DBP, diastolic blood pressure; DM, diabetes mellitus; DR, diabetic retinopathy; HT, hypertension; MA, microalbuminuria; SBP,
systolic blood pressure; T1DM, type I diabetes mellitus; VEGF, vascular endothelial growth factor.
Data are presented as means±s.d., albumin excretion rate as (min and max).
*Group with T1DM with HT and with MA/DR vs group without HT and MA/DR.
**Group with T1DM with HT and MA/DR vs group without HT and with MA/DR.
***Group with T1DM with HT and MA/DR vs healthy subjects.
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rank order method. Normal variables were analysed
using parametric methods, that is the Student’s
t-test, ANOVA, Pearson’s correlation.
To investigate factors influencing serum VEGF
concentration, a general linear model was fitted. The
model included age, sex, HbA1c, duration of
disease, albumin excretion rate, systolic and diasto-
lic blood pressure as the independent variables. In
all analyses, a two-tailed significance level of o0.05
was regarded as statistically significant.
Results
Clinical and biochemical parameters of patients with
T1DM
The group of T1DM patients with HT and MA/DR
was older and with a longer duration of the disease,
a higher level of HbA1c, higher C-reactive protein, a
higher daily excretion of albumin and higher
pressure, both systolic and diastolic in comparison
with the group of patients without HT and MA/DR.
On the other hand, when comparing the same group
of T1DM patients with HT and without MA/DR
with the group without HT, but with MA/DR, no
statistically significant differences were shown in
age, duration of the disease, CRP level or daily
excretion of albumin. Statistically significant differ-
ences were shown only in the level of HbA1c and in
systolic and diastolic pressure.
In addition, when comparing the group of T1DM
patients with HT onto the healthy group, signifi-
cantly higher levels of HbA1c, CRP, albumin extrac-
tion rate and elevated systolic and diastolic blood
pressure were observed than in healthy subjects
(Table 1).
Levels of VEGF in T1DM patients
The highest level of VEGF was in group T1DM
patients with HT and MA/DR as compared with
T1DM patients without HT and MA/DR (P¼0.035)
as well as T1DM patients without HT, but with MA/
DR (P¼0.036). In addition, a statistically signifi-
cantly higher level of VEGF was observed in T1DM
patients with HT and MA/DR as compared with the
healthy subjects (P¼0.0000) (Table 1). Moreover, a
statistically significantly lower (P¼0.001) serum
level of VEGF was observed in T1DM patients
without HT and MA/DR in comparison with T1DM
patients without HT, but with MA/DR. On the other
hand, when comparing the group of T1DM patients
without HTand MA/DR to the control group, we did
not note any statistically significant differences
(P¼0.19) in the level of VEGF (Figure 1).
Univariate correlation between systolic and diastolic
blood pressure and VEGF level in T1DM patients
In T1DM patients, we observed a statistically
significant correlation between systolic blood pres-
sure and serum VEGF level (Spearman r¼0.4;
P¼0.00004) (Figure 2) as well as between systolic
blood pressure and HbA1c level (Spearman r¼0.5;
P¼0.000002) (Figure 3) and a correlation of low
significance between diastolic blood pressure and
serum VEGF level (Spearman r¼0.2; P¼0.041)
Figure 1 Levels of VEGF in T1DM patients. DM with HT with
MA/DR—diabetes mellitus with HT and MA and/or DR. DM
without HT and MA/DR—diabetes mellitus without HT and MA
and/or DR. DM without HT and with MA/DR—diabetes mellitus
without HT and with MA and/or DR. The figure represents
significantly higher level of VEGF patients with T1DM and HT
and with MA/DR vs T1DM patients without HT and MA/DR
(*P¼0.035) and significantly higher level compared with
diabetes mellitus (DM) group without HT and with MA/DR (**P¼
0.036) as well as with the healthy subjects (***P¼0.00000).
Moreover, it represents significantly (
yP¼0.001) lower level of
VEGF in DM group without HT and MA/DR vs DM without HT
and with MA/DR, as well as lack of significance (
zP¼0.19) in
comparison with the healthy group.
Figure 2 Correlation between systolic blood pressure and VEGF
level in T1DM patients. A statistically significant correlation
between systolic blood pressure and serum VEGF was observed.
Spearman’s rank correlation (r¼0.4, P¼0.0004) for all T1DM
patients.
Serum VEGF level and hypertension
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between other baseline variables.
Multivariate analysis
To better assess the possible relationship between
VEGF and the other variables, a multiple regression
model (general linear model based) was created. The
model included VEGF level as the dependent
variable and the independent variables were age,
sex, duration of disease, HbA1c, albumin excretion
rate, systolic and diastolic blood pressure. The
results of the analysis are displayed in Table 2.
After adjustment for possible confounders, only
systolic blood pressure (b¼0.28; P¼0.022), HbA1c
(b¼0.22; P¼0.026) and duration of diabetes
(b¼0.20; P¼0.050) proved to be independent
factors influencing serum VEGF concentration.
This model was statistically significant and ex-
plained 30% of total VEGF variation in examined
patients.
Discussion
The core of our research is that our patients with
T1DM with HTand MA/DR really do reveal a higher
level of VEFG in serum compared with T1DM
patients who do not have HT, as well as in
comparison with the healthy control group. In
addition, the VEGF level was significantly higher
in T1DM patients who presented all three complica-
tions that is HT, retinopathy and MA in comparison
with T1DM patients without HT, but with retino-
pathy and MA. However, no statistically significant
difference was found on the VEGF level in serum
between the T1DM group without HT and MA/DR
and the healthy control group. These data indicate
that the VEGF level is not significantly higher in
these patients, compared with the healthy control
group, as long as patients with type I diabetes
have not developed any complications. Moreover,
patients with MA, retinopathy and HT have the
highest level of VEGF secretion, whereas the lowest
secretion appears in patients who have no compli-
cations. Our results indicate that VEGF may be a
potential mediator in the early phase of microvessel
lesion in the history of HT in children and
adolescents with type I diabetes. Diabetic patholo-
gical changes in the microcirculation of the retina,
renal glomerule and nerve vessels have a similar
pathogenic basis.
13,15,18
However, despite vast research conducted, there
is no unanimous agreement as to the frequency and
reasons for HT in children with type I diabetes who
have developed microangiopathy. It is known that,
on the one hand, HT accelerates and reinforces
Figure 3 Correlation between systolic blood pressure and HbA1c
level in T1DM patients. A statistically significant correlation
between systolic blood pressure and HbA1c level (r¼0.5,
P¼0.000002) was observed. Spearman’s rank correlation
(r¼0.5, P¼0.000002) for all T1DM patients.
Figure 4 Correlation between diastolic blood pressure and VEGF
level in T1DM patients. The correlation between diastolic blood
pressure and serum VEGF level was calculated. Spearman’s rank
correlation (r¼0.2, P¼0.041) for all T1DM patients.
Table 2 Results of multiple regression analysis with VEGF as the
dependent variable (adjusted R
2¼0.30; Po0.001)
DV:VEGF b  95%CI +95%CI P-value
HbA1c 0.22 0.03 0.42 0.026
MA 0.08  0.13 0.29 0.439
Age 0.08  0.17 0.32 0.531
SBP 0.28 0.04 0.53 0.022
DBP 0.06  0.15 0.28 0.551
Duration of DM 0.20 0.00 0.40 0.050
Sex  0.11  0.29 0.07 0.231
Abbreviations: DBP, diastolic blood pressure; DM, diabetes mellitus;
Duration of DM, duration of disease; DV, dependent variable; b,
standard coefficient of regression; 95%CI, 95% confidence interval for
b; MA, microalbuminuria; SBP, systolic blood pressure; VEGF,
vascular endothelial growth factor.
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Journal of Human Hypertensionmicro- and macrovascular complications in dia-
betes; on the other hand, in patients with type I
diabetes who suffer from diabetic nephropathy,
arterial HT is considered to be the secondary result
of kidney lesion.
34,35 In recent years, the necessity
for the 24-h measurement of blood pressure in
patients with T1DM has been raised to monitor
and discover early changes in the blood pressure
profile, manifested by the drop of blood pressure
during the night, which may be the first symptom of
microangiopathy.
34,36,37
Our earlier research, as well as publications from
other authors,
16,21–24 indicates that VEGF can be an
important factor influencing complications related
to microangiopathy in patients with type I diabetes;
however, never have we met any report on the
relation between VEGF and HT in the course of
diabetic microangiopathy of children and adoles-
cents suffering from T1DM. Our current research
indicates a considerably different interchangeable
higher level of HbA1c and systolic pressure in
patients with MA, retinopathy and HT, next to a
considerably higher level of VEGF, as compared
with patients who also suffer from MA and retino-
pathy, but have no HT. A similar conclusion may be
drawn from the research of Torchinsky et al.,
38 who
have shown that, in the group of patients with poor
metabolic control of diabetes, an increase in arterial
blood pressure is observed at an early stage of the
disease with consequent incidence of MA. It is
know that VEGF synthesis occurs in podocytes in
the glomerular and tubular cells as well as collecting
channels and VEGF receptors are present in glomer-
ular endothelial cells.
20,39 Recent in vitro studies
have shown a significant increase in VEGF levels,
synthesized in the podocytes in high glucose
patients.
20 An increased VEGF in the glomerular
endothelial cells may contribute to the development
of MA by increasing glomerular permeability
through various mechanisms in diabetic pa-
tients.
20,40
Recently, researchers have indicated in their
works that MA is not only the symptom of develop-
ing diabetic nephropathy, but, also lesions in the
organ of vision. It is suggested that in patients with
T1DM, the elevated values of arterial blood pressure
are associated with the development of DR inde-
pendently of incipient nephropathy.
7,9 Such a
scenario has also been postulated by large-scale
studies, such as, for example, the prospective study
by Gallego et al. carried out on a group of
adolescents with juvenile onset of type I DM who
were affected by the development of early retino-
pathy. These authors have postulated that both
systolic and diastolic blood pressures are predictors
of retinopathy and increase the probability of early
retinopathy independently of incipient nephropa-
thy in young patients with T1DM.
9
Our research additionally reveals the correlation
between systolic pressure and the VEGF level. The
results of multiple regression analysis indicate that
systolic blood pressure is an equally important
independent variable, influencing VEGF, as HbA1c
and the duration of the disease are.
It has not been fully discovered how HT leads to
the increased production of VEGF in T1DM patients.
It is believed that this is a multi-directional process.
On the one hand, it is known that persistent
hyperglycaemia, leading to the elevation of HbA1c
level, may lead to the production and accumulation
of advanced glycation end-products. The formation
of advanced glycation end-products promotes pro-
duction of pro-inflammatory cytokines, which may
further initiate the increase of VEGF level, thus
indirectly leading to the development of HT. It was
proved that VEGF combines with the VEGFR-2
receptor on the surface of endothelium cells, which
leads to the phosphorylation of transcription factors
by MAPK kinase (miogen-activated protein ki-
nase).
17,25 As a result of this process, there occurs
an increased expression of adhesive molecules,
along with an increase in cytokines and chemo-
kines, which foster the proliferation of endothelium
cells and the production of an extracellular matrix
and at the same time impair its degradation.
19–20
Consequently, the increasing fibrosis of vessels
appears, the vascular lumen decreases, so the blood
flow through the vessels is hindered. The increased
resistance in the blood system further results in the
increased production of VEGF and fosters changes
in the structure and proportion of collagen and
elastine, thus leading to higher rigidity of vessels
and aggravated HT.
Summing up, the results of our research indicate
that VEGF is an important factor in the pathogenesis
of microangiopathy in cases of this type of HT.
Paediatricians are interested in receiving therapeu-
tic tools for young patients with diabetes, aiming at
limited complications on the microvascular level.
Rivard et al.
41 attempted to use the methods of gene
therapy using adeno-VEGF in non-obese mice
(NOD). They reported that inhibition of VEGF
expression may contribute to the inhibition of late
diabetic complications or to their complete remis-
sion. Besides, Fernandez et al.
42 showed on an
animal model that therapy aimed at inhibition of
VEGF and PDGF has a significant function in the
inhibition of portal HT, causing its reduction even
by 40%. In addition, the results of first clinical
studies with the participation of T1DM patients are
encouraging and maybe in the near future medica-
tions inhibiting VEGF will become the principle of
the therapy of microangiopathy.
43–45 Nevertheless,
before this becomes true, it is important to monitor
VEGF levels in a larger group of patients,
which would allow for the identification of a
subgroup of patients with the highest risk of the
incidence of HT and subsequently late diabetic
complications. VEGF may become a marker useful
in identification of the patients who in the future
might develop HT before the occurrence of the first
clinical signs of HT.
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